<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00940953</url>
  </required_header>
  <id_info>
    <org_study_id>CDX313CT001</org_study_id>
    <secondary_id>P2DS07001</secondary_id>
    <nct_id>NCT00940953</nct_id>
  </id_info>
  <brief_title>Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study Comparing Relative Efficacy of CE Budesonide+Azelastine &amp; Rhinocort Aqua+Astelin Nasal Sprays Against Placebo in the Treatment of AR in an EEC Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ligand Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ligand Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study was to compare Placebo to Captisol-Enabled Budesonide +
      Azelastine in a single spray and two separate sprays (Budesonide + Azelastine) in patients
      with Seasonal Allergic Rhinitis exposed to controlled ragweed pollen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient-rated Total Nasal Symptom Score</measure>
    <time_frame>10 mins, 20 mins, 30 mins, 40 mins, 60 mins, 90 mins, 120 mins and then every hour up to 10 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-rated Total Symptom Score</measure>
    <time_frame>10 mins, 20 mins, 30 mins, 40 mins, 60 mins, 90 mins, 120 mins and then every hour up to 10 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-rated EEC-RQLQ assessment</measure>
    <time_frame>-0.75 hours, 2 hours, 6 hours and 10 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Captisol-Enabled Budesonide + Azelastine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rhinocort Aqua+Astelin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide + Azelastine</intervention_name>
    <description>nasal spray, one spray per nostril at time 0 plus one spray Placebo</description>
    <arm_group_label>Captisol-Enabled Budesonide + Azelastine</arm_group_label>
    <other_name>CDX-313</other_name>
    <other_name>Captisol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide + Azelastine</intervention_name>
    <description>nasal spray, one spray of each per nostril at time 0</description>
    <arm_group_label>Rhinocort Aqua+Astelin</arm_group_label>
    <other_name>Rhinocort Aqua</other_name>
    <other_name>Astelin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>nasal spray, one spray per nostril from each of 2 bottles at time 0</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>phosphate buffered saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a clinical history of SAR

          -  Adults (males and females) aged 18 to 65

          -  Patients must have documentation of a positive skin test within 12 months of screening
             to ragweed allergen defined by a positive case history and a positive skin prick
             and/or intradermal test for ragweed allergen.

          -  Non-pregnant, non-lactating females, or women who are post-menopausal or are naturally
             or surgically sterile

          -  Females of childbearing potential must have a confirmed absence of pregnancy according
             to a negative urine pregnancy test and must be using acceptable birth control methods

          -  In generally good health on the basis of medical history and physical examination.

          -  Willingness to attend all study visits.

          -  Capable of following and understanding instructions.

          -  Willing and able to provide written informed consent prior to initiation of any study
             procedures, including initiation of washout of any concomitant medications

        Exclusion Criteria:

          -  Pregnancy, nursing, or plans to become pregnant or donate gametes (ova or sperm) for
             in-vitro fertilization

          -  Have clinically significant physical findings of nasal anatomical deformities causing
             greater than 50% obstruction based on the clinical estimate of the investigator,
             including nasal polyps, septal defects or other clinically significant respiratory
             tract malformations, recent nasal biopsy, nasal trauma, or surgery and atrophic
             rhinitis or rhinitis medicamentosa

          -  Previous participation in a budesonide study within 1 month prior to the Screening
             Visit.

          -  Currently participating in a clinical trial or has been exposed to an investigational
             treatment within the 30 days prior to the Screening Visit.

          -  A known hypersensitivity to any corticosteroid or any of the excipients in the
             formulation of the investigational drug (e.g., any adverse experience with budesonide,
             azelastine or the Captisol-containing products Vfend IV or Geodon IM).

          -  History of severe respiratory infection or disorder

          -  History of alcohol or drug abuse

          -  History of a positive test for HIV, hepatitis B or hepatitis C.

          -  Use of any of the prohibited medications within the identified exclusion periods

          -  Use of antibiotic therapy for acute conditions

          -  Initiation of immunotherapy or dose escalation during the study period.

          -  Non-vaccinated exposure to or active infection with chickenpox or measles within the
             21 days preceding the Screening Visit.

          -  Exposure to systemic corticosteroids

          -  Use of topical corticosteroids in concentrations in excess of 1% hydrocortisone or
             equivalent

          -  History of epilepsy or seizures

          -  History of coronary heart disease, uncontrolled hypertension, or other clinically
             significant cardiovascular disease.

          -  Have any of the following conditions that are judged by the investigator to be
             clinically significant and/or affect the patient's ability to participate in the
             clinical trial:

               -  Impaired hepatic function including alcohol related liver disease or cirrhosis

               -  History of ocular disturbances (e.g., glaucoma or posterior subcapsular
                  cataracts)

               -  Any systemic infection

               -  Hematological, renal, endocrine (except for controlled diabetes mellitis or
                  postmenopausal symptoms or hypothyroidism)

               -  Gastrointestinal disease

               -  Malignancy (excluding basal cell carcinoma)

               -  A current neuropsychiatric condition with or without drug therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepen Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allied Research International - Cetero Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allied Research International - Cetero Research</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4W 1N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2009</study_first_submitted>
  <study_first_submitted_qc>July 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2009</study_first_posted>
  <last_update_submitted>October 2, 2012</last_update_submitted>
  <last_update_submitted_qc>October 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Azelastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

